Researchers at Cedars-Sinai have found that a blood test can help identify pregnant women at risk of developing a severe form of the blood pressure disorder preeclampsia.

They discovered that a specific imbalance of two placental proteins could be used to predict which women would develop preterm preeclampsia.

The researchers conducted a blinded, prospective study, which was published in the journal NEJM Evidence.

The study was conducted across 18 US hospitals in 1,014 pregnant women who are initially hospitalised for preterm hypertension.

Cedars-Sinai researchers found that a specific protein imbalance in the hospitalised pregnant women provided a path to identify their risk of developing severe preeclampsia.

They measured the ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) in pregnant women’s blood samples.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cedars-Sinai Department of Obstetrics and Gynecology chair Sarah Kilpatrick said: “This test was significantly better than all the standard-of-care markers for preeclampsia with severe features.

“It predicted with over 90% accuracy whether the patient would develop preeclampsia with severe features or not, while the usual markers were accurate less than 75% of the time.

“Having an accurate test would help us ensure that the mother was in the right hospital for management of her care and that of her preterm baby.”

Delivery is currently the only cure for preeclampsia.

Cedars-Sinai noted that a test that can indicate a preterm pregnant woman who is likely to develop severe disease can help in optimising care.

The findings from the study are also expected to point the way for potential drug therapies for women who are at risk.